Biogen Q2 revenues up 8%; earnings up 72%

Biogen (NASDAQ:BIIB) Q2 results ($M): Revenues: 3,617 (+7.7%).

Net income: 1,494 (+72.3%); non-GAAP net income: 1,742 (+44.9%); EPS: 7.85 (+87.8%); non-EPS: 9.15 (+57.8%).

Key product sales: Tecfidera: 1,150 (+5.8%); Spinraza: 488 (+15.4%); Tysabri: 475 (+1.7%); Avonex: 438 (-12.7%); Rituxan/Gazyva: 394 (+4.5%); Ocrevus royalties: 183 (+61.9%).

Previously: Biogen EPS beats by $1.61, beats on revenue (July 23)

https://seekingalpha.com/news/3480044-biogen-q2-revenues-8-percent-earnings-72-percent